Organigram (TSE:OGI) PT Raised to C$3.60

Organigram (TSE:OGI) had its price target raised by Canaccord Genuity Group from C$3.25 to C$3.60 in a report issued on Wednesday, BayStreet.CA reports. They currently have a speculative buy rating on the stock.

Separately, Jefferies Financial Group cut their price objective on shares of Organigram from C$4.40 to C$4.35 in a report on Friday, May 17th.

Organigram Price Performance

TSE:OGI opened at C$2.79 on Wednesday. The company has a debt-to-equity ratio of 1.55, a current ratio of 6.95 and a quick ratio of 2.62. The company has a 50 day moving average price of C$2.22 and a 200-day moving average price of C$2.53. Organigram has a 1-year low of C$1.35 and a 1-year high of C$3.95. The firm has a market cap of C$287.37 million, a price-to-earnings ratio of -1.11, a price-to-earnings-growth ratio of 0.42 and a beta of 1.13.

Insider Transactions at Organigram

In related news, Senior Officer Paolo De Luca sold 11,899 shares of Organigram stock in a transaction on Thursday, May 23rd. The shares were sold at an average price of C$2.61, for a total value of C$31,056.39. Corporate insiders own 27.16% of the company’s stock.

About Organigram

Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O’ Buds, Monjour, Trailblazer, SHRED’ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.